-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation
NEW YORK, NY / ACCESS Newswire / August 11, 2025 / New to The Street proudly spotlights its esteemed client, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), which today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression.
This designation represents a 10-fold expansion in the potential patient population compared to the FDA's 2017 Fast Track designation for bipolar depression alone - now encompassing the 13 million U.S. adults who consider suicide each year. The FDA's decision also recognizes NRX-100's potential to address an unmet medical need, qualifying it for eligibility under the Commissioner's National Priority Voucher Program (CNPV) and accelerated approval pathways.
Supported by multiple large-scale, well-controlled trials - including pivotal studies from Columbia University and the Government of France - NRX-100 (preservative-free IV ketamine) demonstrated rapid and statistically significant reductions in suicidal ideation, in some cases doubling remission rates compared to placebo.
"We thank the FDA for its thoughtful review of our Fast Track designation request," said Dr. Jonathan Javitt, Chairman & CEO of NRx Pharmaceuticals. "This recognition is a major step toward addressing the national crisis of suicide affecting civilians, soldiers, veterans, and first responders. We are committed to working closely with the FDA to bring this life-saving therapy to those who need it most."
"At New to The Street, we are honored to help share NRx Pharmaceuticals' groundbreaking achievements with millions of viewers across our national television platforms," said Vince Caruso, Co-Founder & CEO of New to The Street. "FDA Fast Track designation is not just a regulatory milestone - it's a pivotal moment in the fight against one of our nation's most urgent public health crises, and we're proud to help amplify this story."
A First-in-Class Formulation
NRX-100's preservative-free formulation offers a key safety advantage by eliminating benzethonium chloride - a toxic preservative found in some ketamine products - and is manufactured in the U.S. with a three-year room-temperature shelf life. The Company has initiated U.S. high-volume manufacturing and filed a Citizen Petition to remove benzethonium chloride from all IV ketamine products.
Next Steps Under Fast Track
Under the program, NRx will seek Accelerated Approval and Priority Review, post an expanded access policy within two weeks, and engage FDA leadership to finalize its data package for review. The Company's goal is to expand access to this potentially life-saving treatment to all Americans, beyond those currently able to pay out-of-pocket.
With the U.S. suicidal depression market estimated at over $3 billion annually, this milestone has both profound societal impact and significant commercial potential.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company developing breakthrough therapeutics based on its NMDA platform to address serious central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The Company's lead candidates include NRX-100, a preservative-free intravenous ketamine formulation awarded Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of suicidal ideation in depression, including bipolar depression, and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone, awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.
NRx has recently filed both an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application (NDA) for NRX-100, alongside an application for the Commissioner's National Priority Voucher Program. These filings are supported by data from well-controlled clinical trials conducted under the auspices of the U.S. National Institutes of Health and the Government of France, licensed to NRx under a formal data-sharing agreement.
For more information, please visit www.nrxpharma.com.
About New to The Street
New to The Street is a leading, nationally broadcast television and multi-platform media brand delivering in-depth profiles of public and private companies, innovative entrepreneurs, and industry leaders. Since 2009, New to The Street has aired weekly on Fox Business and Bloomberg as sponsored programming, reaching over 224 million homes weekly across the U.S. and internationally. Its New to The Street TV YouTube channel boasts 3.17 million subscribers, making it one of the largest financial media channels on the platform. Company-wide, New to The Street commands an audience of over 711,000 followers across X, Facebook, LinkedIn, and Instagram, delivering unmatched social media amplification.
Beyond TV and digital, New to The Street generates over 20 million monthly outdoor billboard impressions through its network of iconic billboards in Times Square and the NYC Financial District, further enhancing visibility for its featured companies. Integrating long-form TV interviews, earned media placements, outdoor campaigns, and proprietary Opportunities To Consider™ segments, New to The Street delivers unparalleled exposure, credibility, and investor reach. Learn more at www.newtothestreet.com.
Media contact
SOURCE: New To The Street
View the original press release on ACCESS Newswire
W.Morales--AT